Event Overview

Immunotherapy holds great promise, but it only works in a subset of cancer patients. To predict which patients will respond positively to certain treatments and track their progress, researchers search for predictive and prognostic immuno-oncology biomarkers.

In this virtual symposium brought to you by The Scientist, an expert panel will discuss their efforts to identify new biomarkers for various cancers, including non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma (ccRCC). They will also highlight the cutting-edge technologies they use to develop clinical applications for these biomarkers.

Symposium program
    10:30 AM – Introduction
    10:40 AM – An Immune Cell Signature to Predict Patient Responses to Immunotherapy
    Thomas U. Marron, MD, PhD
    11:10 AM – How Computational Modeling Informs Trial Design and Biomarker Discovery
    Johannes Textor, PhD
    11:40 AM – Anti-PD-1 Response and Resistance Determinants in Clear Cell Renal Cell Carcinoma
    Lewis Au, MD, PhD
    12:10 PM – Cancer Proteogenomics to Understand Immune Evasion and Discover Drug Targets
    Janne Lehtiö, PhD
    12:40 PM – Open panel Q&A session
Thursday, May 12, 2022
10:30 AM - 1:30 PM Eastern Time

Meet the speakers

Thomas U. Marron, MD, PhD
Director, Early Phase Trials Unit
The Tisch Cancer Institute
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai

Johannes Textor, PhD
Associate Professor
Tumor Immunology Department
Radboud University Medical Center
Group Leader
Institute for Computing Information Sciences
Radboud University

Lewis Au, MD, PhD
Clinical Research Fellow
Royal Marsden Hospital
Translational Research Scientist
Francis Crick Institute
Janne Lehtiö, PhD
Department of Oncology and Pathology
Karolinska Institute and SciLifeLab


TS_Webinar_Symposium_Biomarkers on the Brain: From Sequencing to Functional Imaging December 13, 2021

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.

Sponsored by